HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting - Episode 4

SABCS 2021: Novel Approaches to Breast Cancer Management

January 24, 2022

Virginia G. Kaklamani, MD, DSc, Anne P. O’Dea, MD, Yara Abdou, MD, Heather McArthur, MD, MPH

After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Coming Soon, HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting

EP. 2: SABCS 2021: Updates in Metastatic Breast Cancer

EP. 3: SABCS 2021: Brain Metastases Updates in Breast Cancer

Now Viewing

EP. 4: SABCS 2021: Novel Approaches to Breast Cancer Management

Data from the following clinical trials are discussed:

GS3-03: Genomic analysis of 733 HER2+ breast cancer identifies recurrent pathway alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities
GS1-05: Datopotamab deruxtecan (Dato-DXd) in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study
GS04-09: Quality-of-life results from OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after neoadjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2- early breast cancer